344 completed, 80 unknown, 64 recruiting, 54 terminated. 621 Phase 2, 98 Phase 1, 93 Phase 3.
Follow Pathological Conditions, Anatomical: new trials by email Literature Review of Pathological Conditions, Anatomical trials Research Report on Pathological Conditions, Anatomical
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| FGF-1 for Intramuscular Injection for the Treatment of Peripheral Arterial Disease FGF-1, Placebo - Peripheral Arterial Disease, Stenosis | Phase 1 / Phase 2 | Not yet recruiting | Venturis Therapeutics, Inc. | 24 | 2028-10-15 | 2026-08-19 |
| The Impact of a Patient Decision Aid on Treatment Choices for Patients With an Unexpected Malignant Colorectal Polyp Shared Decision Making using a Patient Decision Aid. - Shared Decision Making, Colonic Polyp | Phase 2 | Not yet recruiting | Vejle Hospital | 110 | 2028-02-01 | 2026-04-30 |
| AV-1959R Vaccine in Individuals With Preclinical Alzheimer's Disease AV-1959R, Placebo - Preclinical Alzheimer's Disease, Alzheimer Disease | Phase 2 | Not yet recruiting | Institute for Molecular Medicine | 160 | 2027-10-01 | 2026-10-21 |
| The FORCE Trial Pilot: Fish Oil-enriched Nutrition for Radiotherapy in Cancer of the hEad and Neck Nutrition counseling, Fresubin Supportan - Head &Amp;Amp; Neck Squamous Cell Carcinoma | Phase 1 / Phase 2 | Not yet recruiting | Anna Arthur, PhD | 15 | 2027-06-01 | 2026-08-07 |
| Evaluate the Efficacy and Safety of EN001 in Patients With Sarcopenia EN001, EN001 Placebo - Sarcopenia | Phase 1 / Phase 2 | Not yet recruiting | ENCell | 132 | 2027-03-01 | 2026-09-11 |
| Efficacy and Safety of TRA16 Administered Orally in Patients With Enteric Hyperoxaluria (EH). TRA16, Placebo - Enteric Hyperoxaluria | Phase 2 | Not yet recruiting | Wuhan Kangfude Urolithiasis Research Institute Co., Ltd. | 30 | 2027-03-01 | 2026-10-13 |
| A 28-Day Study of GAL-101 in Participants With Mild to Moderate Alzheimer's Disease GAL-101 Salt, Placebo - Mild to Moderate Alzheimer's Disease | Phase 2 | Not yet recruiting | Galimedix Therapeutics Inc | 100 | 2027-02-28 | 2026-08-27 |
| XVIE to Treat Androgenetic Alopecia (AGA) Decellularized allogeneic human amniotic fluid, Sodium chloride 0.9% injectable solution - Androgenetic Alopecia | Phase 1 / Phase 2 | Not yet recruiting | Restore Biologics Holdings, Inc. dba Xtressé | 30 | 2026-12-01 | 2026-08-12 |
| HMB Plus Vitamin D to Preserve Muscle in Older Adults Starting Semaglutide Calcium-HMB Plus Vitamin D3, Matching placebo - Type 2 Diabetes Mellitus (T2DM), Sarcopenia | Phase 2 | Not yet recruiting | Vanderbilt University Medical Center | 90 | 2026-12-01 | 2026-08-28 |
| Efficacy of Botulinum Toxin A Versus Nanofat in the Treatment of Androgenetic Alopecia: A Comparative Clinical Trial Botulinum Toxin Type A, Autologous Nanofat Injection - Androgenetic Alopecia | Phase 2 / Phase 3 | Not yet recruiting | Sherief Ayman Hussein Shaamash | 40 | 2026-12-01 | 2026-10-07 |
| Phase 2 Efficacy and Safety of PP405 in Adult Females With Androgenetic Alopecia PP405 0.05% Topical Gel, Vehicle Topical Gel - Androgenetic Alopecia | Phase 2 | Not yet recruiting | Pelage Pharmaceuticals, Inc. | 200 | 2026-11-01 | 2026-10-30 |
| A Phase 2, Placebo-Controlled Study of Oral RXC008 for Crohn's Strictures High Dose, Low Dose, Placebo - Strictures Due to Crohn's Disease | Phase 2 | Not yet recruiting | Redx Pharma Ltd | 180 | 2026-10-01 | 2026-09-22 |
| Phase 2/3 Efficacy and Safety of PP405 in Adult Males PP405 0.05% Topical Gel, Vehicle Topical Gel - Androgenetic Alopecia | Phase 2 / Phase 3 | Recruiting | Pelage Pharmaceuticals, Inc. | 600 | 2026-09-21 | 2026-10-28 |
| MANTIS-RCC: Toripalimab-Axitinib Induction in TLS-Positive Advanced Non-Clear Cell and Renal Medullary Carcinomas Toripalimab, Axitinib, Deferred Cytoreductive Nephrectomy - Metastatic Non-Clear Cell Renal Cell Carcinoma, Metastatic Renal Medullary Carcinomas | Phase 2 | Not yet recruiting | Fudan University | 30 | 2026-09-20 | 2026-09-14 |
| Study of YOLT-203 in Children and Adults With Primary Hyperoxaluria Type 1 (PH1) YOLT-203, Placebo - Primary Hyperoxaluria Type 1, PH1 | Phase 2 | Recruiting | YolTech Therapeutics Co., Ltd | 36 | 2026-09-16 | 2026-10-09 |
| Tirzepatide for Treatment of CCCA Tirzepatide - Central Centrifugal Cicatricial Alopecia (CCCA) | Phase 2 | Recruiting | Johns Hopkins University | 20 | 2026-09-15 | 2026-11-03 |
| ATR 1072 in Participants With PRKAG2 Syndrome ATR 1072 - Cardiac Glycogenosis, Cardiomyopathy | Phase 1 / Phase 2 | Recruiting | Atrium Therapeutics | 37 | 2026-09-14 | 2026-09-18 |
| Trial of Delgocitinib 20 mg/g Cream in Subjects With Frontal Fibrosing Alopecia (FFA) Delgocitinib - Frontal Fibrosing Alopecia | Phase 2 | Not yet recruiting | Maryanne Makredes Senna | 30 | 2026-09-10 | 2026-08-26 |
| Low-cost Screening and Image-guided Photodynamic Therapy (PDT) of Premalignant and Malignant Oral Lesions 5-Amino Levulinic Acid - Oral Cancer, Oral Cavity Cancer | Phase 2 | Not yet recruiting | University of Massachusetts, Boston | 65 | 2026-09-01 | 2026-03-19 |
| SCALp Cooling for pReventing aLopecia With nEw anTibody-drug Conjugates scalp cooling, photographs via the Belle.AI app, Antibody-Drug Conjugates - Advanced or Metastatic Solid Tumour, Antibody-Drug Conjugate | Phase 2 | Not yet recruiting | Jules Bordet Institute | 102 | 2026-09-01 | 2026-08-19 |
Showing 20 of 621. Sign in to see all of them.
Alopecia (115) · Plaque, Amyloid (47) · Sarcopenia (47) · Muscular Atrophy (45) · Kidney Calculi (37) · Nasal Polyps (27) · Fistula (19) · Hernia, Inguinal (19) · Hernia (18) · Hypertrophy, Left Ventricular (18) · Pain, Postoperative (18) · Alzheimer Disease (17) · Constriction, Pathologic (15) · Alopecia Areata (14) · Leukoplakia, Oral (14)
Pathological Conditions, Signs and Symptoms (621) · Skin and Connective Tissue Diseases (143) · Signs and Symptoms (141) · Skin Diseases (133) · Nervous System Diseases (132) · Neurologic Manifestations (126) · Hypotrichosis (114) · Hair Diseases (113) · Pathologic Processes (110) · Neuromuscular Manifestations (86) · Urogenital Diseases (86) · Female Urogenital Diseases and Pregnancy Complications (82) · Atrophy (81) · Female Urogenital Diseases (80)
Minoxidil (19) · Bupivacaine (10) · Sodium Chloride (9) · Finasteride (7) · Solutions (7) · Saline Solution (6) · ruxolitinib (6) · Mometasone Furoate (5) · beta-hydroxyisovaleric acid (5) · bimagrumab (5) · Doxycycline (4) · Gels (4) · Injections (4) · Metformin (4) · Riboflavin (4)
Aderans Research Institute (11) · Novartis Pharmaceuticals (10) · Mayo Clinic (8) · Institut Bergonié (6) · National Cancer Institute (NCI) (6) · Assistance Publique - Hôpitaux de Paris (5) · M.D. Anderson Cancer Center (5) · Massachusetts General Hospital (5) · Allena Pharmaceuticals (4) · Allergan (4) · Beni-Suef University (4) · Brigham and Women's Hospital (4) · Eisai Inc. (4) · Icahn School of Medicine at Mount Sinai (4) · Johns Hopkins University (4)
United States (287) · Canada (42) · Germany (34) · Spain (30) · United Kingdom (30) · China (27) · France (27) · Netherlands (24) · Belgium (22) · Italy (21) · Denmark (20) · Australia (19) · Egypt (16) · Israel (16) · South Korea (15)
Hany F Badawy, MD (4) · David Prior (3) · Yusuf Yazici, M.D. (3) · Amy Lightner, MD (2) · Annamaria Kausz, MD MS (2) · Christina Weng (2) · Claus Bachert, MD, PhD (2)
PMID 33710614, PMID 39532605, PMID 39584361, PMID 16765803, PMID 16952090, PMID 22792007, PMID 22900785, PMID 28619556, PMID 33773598, PMID 34289971, PMID 38263353, PMID 39356039, PMID 41917311, PMID 42481842, PMID 10434461, PMID 11403367, PMID 12172314, PMID 12423712, PMID 12621133, PMID 12719068, PMID 12756590, PMID 14520092, PMID 14578723, PMID 14639093, PMID 14700505, PMID 14704728, PMID 15253184, PMID 15273542, PMID 15362760, PMID 15716707, PMID 16079683, PMID 16160130, PMID 16565005, PMID 16583638, PMID 16900027, PMID 16942935, PMID 17077737, PMID 17312203, PMID 17444886, PMID 17457183, PMID 17457184, PMID 17531694, PMID 17551129, PMID 17637792, PMID 17720054, PMID 17762662, PMID 17981197, PMID 18074068, PMID 18358585, PMID 18464745
2017 (6), 2015 (5), 2023 (5), 2016 (4), 2019 (3), 2025 (3), P30CA016672 (3), 2008 (2), 2018 (2), N01CN35159 (2), P30CA023074 (2), P50DK083007 (2), UL1RR024150 (2), 1UG3DE030401-01 (1), 2005 (1)